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Glypican-3 (GPC3) targeted Fe3O4 core/Au shell
nanocomplex for fluorescence/MRI/photoacoustic
imaging-guided tumor photothermal therapy†
Rui Tian,‡a Lei Zhu, ‡b Zainen Qin,b Guohao Wang,b Jingjing Wangb and
Hui Zhang*a
Low binding affinity and lack of therapy functions limit tumor targeting peptide applications in the bio-
medical field. Herein, we successfully modified a previous phage display derived Glypican-3 (GPC3)
binding peptide (GBP) on the surface of a Fe3O4 Core/Au shell nanocomplex (FANP) to improve GBP
binding affinity and enhance FANP tumor photothermal therapy (PTT) efficacy. As a result, GBP-FANP
showed improved avidity to GPC-3 (Apparent Kd = 396.3 ± 70.8 nM) compared to that of GPB (Apparent
Kd = 735.2 ± 53.6 nM). After intravenous administration, GBP-FANP was found specifically accumulated in
GPC-3 positive HepG2 tumors and peaked at 24 h post-injection as observed by magnetic resonance
imaging (MRI)/photoacoustic (PA)/fluorescent imaging. Moreover, HepG2 tumors that received
GBP-FANP treatment were significantly inhibited with laser irradiation (630 nm, 1 W cm−2, 10 min). In con-
clusion, our present strategy provides a way of improving peptide ligand avidity with nanotechnology for
cancer theranostics applications.
Background
Cancers continue to be the second leading cause of death
worldwide.1 Despite the development and improvement of
surgery, chemotherapy and radiotherapy in cancer manage-
ment, effective tumor ablation strategies are still in need due
to high cancer patient mortality. In recent decades, targeted
therapy, which specifically kills cancer cells or inhibits cancer
cell growth with less toxicity to normal cells, has attracted a
great deal of interest.2–4
With the facility of molecular biology, a great number of
disease targets and corresponding ligands have been identi-
fied. In particular, peptides are attractive small molecules for
targeted diagnosis and therapeutics applications.5–9 Typically,
such functional peptides are identified through two
approaches: (1) screening of peptide libraries and (2) the
sequencing of bioactive peptides from natural proteins. With
these techniques, increasing numbers of peptides have been
successfully discovered and characterized including somato-
statin (SST) peptide, Arg-Gly-Asp (RGD) peptide, and bombe-
sin/gastrin-releasing peptide (BBN/GRP).10,11 Encouragingly,
over 60 peptides have been approved worldwide during the last
two decades for different diseases treatments,12,13 demonstrat-
ing the promise of peptides in clinical translational study.
Compared to other targeting ligands, such as monoclonal anti-
bodies (mAbs), small molecules and antisense oligonucleo-
tides, peptides have the advantages of low immunogenicity,
clear compositions, stable physicochemical properties and
easy chemical modifications, which are very important for
large-scale production of peptides at relative low cost.11,14
However, enthusiasm for peptides as targeted disease
detection and therapy tools is tempered by the inherent limit-
ations of native peptides,15,16 such as the lack of therapeutic
potency, the short in vivo half-life and relative low binding
affinity. Obviously, the strategies of overcoming such problems
and improving peptides’ in vivo behaviors are eagerly
anticipated.
In recent years, nanomaterials are becoming prominent in
technological fields due to their large surface-to-volume ratio,
excellent electrical and thermal conductivity, strong light
absorption and scattering resulting in enhanced performance
over their bulky counterparts. It has been acknowledged that
avidity to the desired target can be enhanced through multi-
valent conjugation of targeting ligands on the surface of
nanoparticles.17–20 IONP is an inorganic nanoparticle (NP)
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that has been approved by the Food and Drug Administration
(FDA) as a contrast enhancement reagent for clinic magnetic
resonance imaging (MRI). Meanwhile, the applications of
IONPs as drug carriers are also under intense study with prom-
ising results.21 However, naked IONPs tend to aggregate or
cause loss of magnetism because of their high surface energies
and chemical activity.22 Considerable efforts have been devoted
to stabilizing and functionalizing IONPs.23–25 For example,
dextran,18 glucose,26 polyethylene glycol(PEG),27 and poly
(methacrylic acid) (PMAA)28 have all been reported for IONP dis-
persion. Besides these polymer coatings, functionalization of
IONPs with inorganic materials can also enhance the stability
of IONPs and will simultaneously endow IONPs with additional
characteristics. Specifically, gold (Au) has been widely studied
as a coating material for IONPs. Such Au shells can act as a
barrier preventing core oxidation and enzymatic degradation as
well as provide an anchorage site for further modification via
rich surface chemistry.29–31 Compared to a single material
alone, the hybrid IONP/Au complex benefits from both compo-
sitions while maintaining the magnetic properties and therefore
is highly promising in tumor theranostics applications.
Herein, we constructed a Glypican-3 (GPC-3) targeted
hybrid Fe3O4@Au core–shell nanoparticle (FANP) for MRI/PA/
fluorescent imaging guided effective tumor photothermal
therapy (PTT) (Fig. 1). GPC-3 is a potential therapeutic target
for treating liver cancer and other cancers.8,32–34 For example,
GPC-3 targeting peptides have been modified onto silica nano-
particles or iron oxide nanoparticles for targeted liver cancer
imaging in vitro and in vivo.35,36 In our system (Fig. 1), an Au
nanoparticle (AuNP) shell was coated onto 15 nm IONP due to
the stable surface chemistry as a coating material and excellent
photothermal property as a PTT agent.37,38 Meanwhile, a near-
infrared-dye, Cy5.5, labeled phage-display derived GPC-3 high
binding peptide, named GBP, was covalently conjugated onto
the surface of the Au shell via the gold–dithiol bond. It is con-
sidered that such multivalent modification of GBP onto FANP
will: (1) increase the binding affinity of GBP to GPC-3, (2)
improve GBP peptide in vivo half-life, and (3) enhance FANP
tumor targetability and specificity to enhance tumor PTT
response. Indeed, GBP-FANP showed a significantly improved
GPC-3 binding affinity (Apparent Kd = 396.3 ± 70.8 nM) in vitro.
In in vivo studies, GBP directed FANP tumor accumulation was
observed increasing gradually with time by MRI/PA/fluorescent
imaging, in which the MRI signal was from the Fe3O4 NP and
the photoacoustic (PA) signal was from the AuNP shell. As a
multimodalities imaging guide, tumors were irradiated by
laser (630 nm, 1 W cm−2, 10 min) for PTT when GBP-FANP
peaked in tumors at 24 h post intravenous administration. As
a result, GPC-3 positive tumor growth was found significantly
inhibited compared to that of GPC-3 negative tumor, with no
obvious systemic toxicity noticed during the study. Overall, our
results provide a promising application of hybrid nanocom-
Fig. 1 Scheme illustration of the preparation of GBP-FANP and design of study.
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plexes in targeted PTT of tumors by modification of small
molecule targeting ligands. More importantly, taking advan-
tage of nanomaterials, we present a way of enhancing phage
displayed peptide targeting avidity and in vivo stability in
cancer theranostic applications.
Results and discussion
Synthesis and characterization of GBP-FANP
Phage display is a widely used technique to obtain novel
peptide ligands. Varieties of peptide sequences have been
identified for different target materials, and peptides that may
have targeting capabilities towards specific biomarkers in cells
or tissues have received special attention in the biomedical
field. GPC-3 is a cell surface protein that is highly expressed in
Hepatocellular carcinoma (HCC) and some other human
cancers. It has potential as a promising target for tumor-
specific therapy. In our previous report, a 12-mer glypican-3
(GPC3) binding peptide with the sequence of
THVSPNQGGLPS, named GBP, was identified by utilizing the
phage display technique.32 In order to further evaluate and
optimize GBP in GPC-3 targeting, we covalently conjugated
GBP onto the surface of hybrid Fe3O4@Au core–shell nano-
particles (FANP). The tumor targeting and therapeutic potency
of GBP-FANP will be analyzed in the following experiments.
First, FANPs were synthesized through a co-precipitation
method as described previously,45 which leads to formation of
gold nanoparticles (AuNPs) shell coating onto the Fe3O4 nano-
particle (NP) cores through polydopamine.39 In order to track
GBP with fluorescent signals, Cy5.5 was labeled onto the
N-terminal of side chain protected GPB. After that, GBP was
modified with Lipoic acid PEG amine onto the C-terminal so
that it can be modified onto FANP via stable Au–dithiol bond
(Fig. S1–S3†). To confirm the construction of GBP-FANP, trans-
mission electron microscopy (TEM) and dynamic light scatter-
ing (DLS) were employed to obtain the morphology and
size information. As TEM and DLS data in Fig. 2a show,
GBP-FANPs exhibited a uniform size with an average diameter
of about 25 ± 4.2 nm, while the bare IONP presented a dia-
meter of 15 ± 3.3 nm, which is caused by the surface AuNP
coating. Next, the successful preparations of GBP-FANP were
also verified by X-ray Powder Diffraction (XRD) and UV-visible-
near infrared (UV-vis-NIR) absorbance spectrum. The diffrac-
tion peaks at 2θ° = 38.3°, 44.2°, 64.5°, and 77.8° are attributed
to Fe–gold, which can be indexed to 111, 200, 220, and 311
lattice planes of gold in a cubic phase, respectively (Fig. 2b). A
specific absorbance peak of Au nanoshell (NS) at around
520 nm and a characterized peak of Cy5.5 at 680 nm were both
found in the GBP-FANP complex simultaneously, compared
with that of 30 nm AuNP (Blue curve) and Cy5.5-GBP (orange
curve) alone (Fig. 2c). Moreover, Fourier Transform Infrared
Fig. 2 Characterization of GBP-FANP. (a) IONP showed 15 ± 3.3 nm in diameter and GBP-FANP showed 25 ± 4.2 nm in diameter as confirmed by
DLS. Inserted: TEM image of GBP-FANP. Scale bar equals to 50 nm. (b) XRD pattern of FANP and Fe3O4 NP. (c) UV-vis-NIR spectra of GBP, Au nano-
shell (AuNS), IONP and GBP-FANP in water. Characterized peaks 550 nm and 680 nm for AuNS and Cy5.5 in GBP-FANP were noticed. Inserted:
GBP-FANP in PBS (1), FBS (2) and DMEM (3). (d) Fluorescent signals of GBP and GBP-FANP, which were conjugated Cy5.5. Slight quenching effect
was observed between Cy5.5 and AuNS. (e) MRI signals of GBP-FANP at different concentrations (containing 5, 10, 25, 50 and 100 µg mL−1 equi-
valent dose of IONP). A concentration dependent MRI signals of GBP-FANP were observed with linear relationship. (f ) Photoacoustic signals of
GBP-FANP with 630 nm laser illumination at different concentrations (25, 50, 100, 150, 200 and 250 µg mL−1 of AuNS). No photoacoustic signals
were detected for IONP alone.
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Spectroscopy (FT-IR) was employed to identify the conjugation
of GBP onto FANP (Fig. S4†). Because of the surface Au coating
and Cy5.5-GBP conjugation, GBP-FANP presented a blue-
black color with good dispersion in different physiological
solutions including phosphate buffered saline (PBS), fetal
bovine serum (FBS), and Dulbecco’s modified Eagle’s
medium (DMEM) (insert, Fig. 2c). We did not notice any pre-
cipitation of GBP-FANP in these buffers, indicating an excel-
lent stability of GBP-FANP for biological applications. Due to
the absorbance spectrum difference of AuNS and Cy5.5, we
consider the quenching effect between them could be very
little. As Fig. 2d presents, fluorescent signals of GBP-FANP
were measured and the Cy5.5 signal in GBP-FANP was not
found to be significantly affected when compared to the
same amount of free Cy5.5 in GBP peptide. This is because
of the absorbance mismatch between AuNS and Cy5.5
(Fig. 2c). To clarify if Au coating will lead to MRI signals from
IONP, different concentrations of GBP-FANP (5, 10, 25, 50,
100 µg mL−1 of equivalent dose of IONP) were imaged under
9.4 T MRI and a concentration dependent T2 map was
observed, as shown in Fig. 2e. The T2 value from FANP was
found to be in linear relationship with FANP concentration.
Because of the strong optical absorbance of the AuNS, we
further evaluated the photoacoustic (PA) signal of GBP-FANP.
In Fig. 2f, GBP-FANP presented a strong PA signal with
630 nm laser illumination, and the PA signals got stronger as
the concentration increased. In comparison, no PA signals
were detected for IONP according to the weak absorbance
spectrum (Fig. 2f, inserted). All these results demonstrated
that GBP-FANP was constructed successfully, and more
importantly, this biocompatible nanocomplex has the poten-
tial to be a fluorescent/PA/MRI imaging agent for GPC-3 tar-
geted imaging and therapy.
Improved binding affinity of GBP-FANP to GPC-3 in vitro
The large surface-volume ratio of nanomaterials provides a
possibility to conjugate more ligands in one platform for
increasing ligand avidity to certain targets, leading to
enhanced targetability and specificity in disease theranostics.
The binding affinity between GPB-FANP and GPC-3 was
measured in this study before moving forward. In order to
detect the binding affinity between GPC-3 and GBP or
GBP-FANP, a biotin was conjugated onto the N-terminal of
GBP in an enzyme-linked immunosorbent assay (ELISA). By
incubation with human recombinant GPC-3 protein, a con-
centration dependent absorbance increase was found for
both biotin-labeled GBP and biotin-labeled GBP-FANP wells
(35, 75, 150, 300, 600, 1200, 2500, or 5000 µM of equivalent
dose of GBP). As shown in Fig. 3, the apparent Kd value of
GBP-FANP to GPC-3 was calculated as 396.3 ± 70.8 nM, which
is higher than that of free GBP at 735.2 ± 53.6 nM. This indi-
cates that the multivalent conjugation of GBP with FANP
indeed improved the avidity to GPC-3. GBP-FANP is promis-
ing as a diagnosis and treatment agent for GPC-3 targeted
therapy.
GPC-3 targetability of GBP-FANP and photothermal effect of
GBP-FANP to tumor cells
HCC is a highly prevalent and lethal neoplasia with high
expression of GPC-3. As a proof-of-concept, the targetability of
GBP-FANP to GPC-3 was evaluated in the HCC tumor cell line,
HepG2. PC3, a GPC-3 expression negative cell line, was chosen
as a control as we used in our previous study.32 After 4 h incu-
bation of GBP-FANP with the above two cell lines, intracellular
GBP-FANP was stained and visualized by prussian blue stain-
ing (Fig. 4a) and fluorescent imaging (Fig. S5†). A large
amount of GBP-FANP is shown to have accumulated in HepG2
cells and only little was found in PC3 cells, which is attributed
to the GPC-3 expression differences in these two cell lines.
Because of the strong photo-thermal conversion property of
Au nanomaterials, we wondered if the excellent specific GPC-3
binding would be beneficial for inhibiting tumor cell growth.
First, the photothermal effect (PTT) of FANP was studied
under laser irradiation in vitro. As shown in Fig. 4b and c,
different concentrations of GBP-FANP (100, 200, 400, and
600 µg mL−1 of equivalent dose of Au) were irradiated with
630 nm laser at 1 W cm−2 for 10 min. According to the
thermal imaging camera, we observed GBP-FANP temperature
increasing with time and peaking at 10 min (Fig. 4b).
Meanwhile, the temperature is also relevant to the concen-
tration of GBP-FANP. A GBP-FANP solution containing 600 µg
mL−1 of Au reached 67 °C in 10 min, while a GBP-FANP solu-
tion containing 100 µg mL−1 of Au only reached 40 °C at
10 min. In order to evaluate if GBP-FANP is stable under
repeated laser irradiation, GBP-FANP was subjected to four
cycles of illumination (Fig. S6†). It is found that the tempera-
ture elevation only decreased less than 4% (from 56.37 °C to
Fig. 3 Apparent Kd of GBP and GBP-FANP to GPC3 determined by
ELISA. Both GBP and GBP-FANP showed concentration dependent
GPC3 binding. The apparent Kd between GBP and GPC3 was calculated
as 735.2 ± 53.6 nM and the apparent Kd between GBP-FANP and GPC3
was calculated as 396.3 ± 70.8 nM.
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54.87 °C), suggesting that GBP-FANP has good NIR photo-
stability, and is beneficial to repeated PTT in long term clinical
treatments.
Next, we performed a cell proliferation inhibition study to
assess the photothermal toxicity of GBP-FANP on HepG2 and
PC3 cells. GBP-FANP complexes without laser irradiation treat-
ment presented negligible cytotoxicity levels and over 65% of
the cells remained alive at a concentration of 400 μg mL−1 (the
equivalent amount of Au). When the concentration is lower
than 200 μg mL−1 (the equivalent amount of Au), over 80% of
cells proliferation were not affected. However, cell viability
decreased when a 630 nm laser was used in irradiating the
GBP-FANP treated cells, which followed a dose-dependent
manner. Only 22.47% ± 1.41% of the GBP-FANP-treated cells
remained alive at a concentration of 400 μg mL−1 (equivalent
amount of Au) when PTT was applied. However, when GPC-3
was blocked by adding free GBP peptide, GBP-FANP treated
HepG2 cells were not significantly affected regardless of laser
irradiation. In addition, we also tested the GBP-FANP target-
ability and toxicity to PC3 cells, and did not observe much tox-
icity in the GPC-3 negative cells due to the low accumulation
of GBP-FANP. More than half (63.39% ± 2.78%) of the PC3
cells were alive even after treatment with laser illumination,
indicating that GBP mediated specific GPC-3 recognition in
tumor cell growth inhibition.
In vivo evaluation of tumor targetability of GBP-FANP by
fluorescence/PA/MRI imaging
With the development of personalized medicine, multimodal-
ity imaging that combines different molecular imaging techno-
logies has been extensively adopted in clinical diagnosis to
overcome limitations of a single imaging mode.40–45 Among
these biomedical imaging techniques, MRI has the highest
spatial resolution (several tens of micrometers) and soft tissue
contrast but shows limited sensitivity. However, PA imaging
can deliver strong optical absorption contrast and high ultra-
sound spatial resolution in deep tissues, locally.46,47 The
imaging depth of PA can reach up to five centimeters in bio-
logical tissues and the spatial resolution can maintain ∼1/200
at all imaging depths.48–50 In addition, PA imaging is well
suited for imaging superficial tissue layers that can sometimes
cause artifacts in MRI images. However, neither MRI nor PA
are generally feasible for real time detection of tumor tissue,
which is necessary to provide visual and tactile information
Fig. 4 In vitro evaluation of GPC3 targetability and toxicity to cancer cells. (a) Visualization of GBP-FANP accumulation in GPC3 positive HepG2 and
GPC3 negative PC3 tumor cells by prussian blue staining. Large amount of GBP-FANP was found accumulated in HepG2 cells, while little was
detected in PC3 cells. Scale bar equals to 50 µm. (b) Real-time thermal images of GBP-FANP in water under 630 nm laser irradiation at different con-
centrations. (c) Temperature changes of GBP-FANP at different concentrations with laser illumination (630 nm, 1 W cm−2, 10 min). (d) Cells viability
with GBP-FANP treatment with and without laser irradiation (630 nm, 1 W cm−2, 10 min). Error bars were based on standard deviations of three par-
allel samples.
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during surgery. Optical imaging, which can provide real-time
whole-body imaging with high sensitivity, is therefore expected
to combine with MRI/PA imaging. Such tri-modality imaging
strategies will be promising to offer whole-body, high resolu-
tion and real-time imaging with high sensitivity for diagnosis
and therapy applications with great translational potency.
A subcutaneous HCC tumor bearing mouse model was
established and GBP-FANPs were then intravenously injected
at a dose of 10 mg kg−1 (200 μg equivalent dose of Au, 1 mg
mL−1). PC3 tumors with low GPC-3 expression were used as a
negative control and received the same amount of GBP-FANP
intravenously. As shown in Fig. 5a, fluorescent images were
taken at indicated time points (1, 2, 4, 6, 12, 24, 48, and 72 h
post-injection) using the IVIS imaging system with 670 nm
excitation and 690 nm emission settings. It can be seen that
fluorescent signals from GBP-FANP increased gradually in
tumors and peaked at 24 h post-injection (p.i.), after which the
signals faded until 72 h in our study. Quantitatively, the
tumor/muscle ratios in HepG2 tumors that received GBP-FANP
were calculated as 1.29 ± 0.58, 1.60 ± 0.41, 2.26 ± 0.41, 2.43 ±
0.4, 3.94 ± 0.32, 6.82 ± 0.53, 5.30 ± 0.62, 3.25 ± 0.37, respect-
ively. In order to verify if GBP-FANP is specific to GPC-3 in vivo,
we used a 10-fold excess amount of GBP peptide to block
GPC-3 in HepG2 tumors 30 min before GBP-FANP was admini-
strated. Consistent with our in vitro results, only weak signals
were detected in HepG2 tumors when GPC-3 was saturated
(T/M ratio: 1.16 ± 0.39, 1.05 ± 0.55, 1.14 ± 0.69, 1.23 ± 0.38,
1.76 ± 0.29, 3.12 ± 0.36, 2.55 ± 0.41, 2.01 ± 0.37). In addition,
Fig. 5 Evaluation of GBP-FANP tumor targetability in vivo by optical, photoacoustic and MRI imaging non-invasively. (a) In vivo NIR fluorescent
imaging of HepG2 and PC3 tumor-bearing mice taken at different times after intravenous injection of GBP-FANP. Red arrows indicate the tumors
location. (b) Tumor/muscle (T/M) ratio of HepG2 and PC3 tumor-bearing mouse model. (c) In vivo PA imaging of blood vessels in the tumor sites at
different time points after intravenous injection of GBP-FANP (containing 10 mg kg−1 of equivalent dose of AuNS). (d) Photoacoustic intensity of
tumor tissues at different time points. (e) T2-Weighted MRI of GBP-FANP accumulation in HepG2 and PC3 tumor bearing mice. Tumors were
scanned before GBP-FANP was administrated as control. Red circle indicated the tumor location. (f ) Quantification of MRI signals in the tumors
prior to and 24 h after administration of GBP-FANP.
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the specificity of GBP-FANP to GPC-3 was also confirmed in
PC3 tumors as only minimal GBP-FANP was observed in GPC-3
negative PC3 tumors (T/M ratio: 1.32 ± 0.61, 1.34 ± 0.42, 1.32 ±
0.33, 1.42 ± 0.33, 1.40 ± 0.46, 1.84 ± 0.22, 1.65 ± 0.34, and 1.35
± 0.21) due to the non-specific enhanced permeable retention
effect (Fig. 5b). The specific tumor accumulation of GBP-FANP
was further analyzed by ex vivo optical imaging after sacrificing
these tumor bearing mice. As Fig. S7† presents, a significantly
higher amount of GBP-FANP remained in tumors at 72 h p.i.
compared to that of blocked HepG2 tumors and PC3 tumors.
We did notice that liver and kidney both showed a strong fluo-
rescent signal, which might be a concern for further appli-
cations. We considered that further increasing FANP biocom-
patibility and in vivo blood half-life (GBP-FANP exists in blood
for over 48 h according to Fig. S8†) with PEG or albumin modi-
fication would reduce such non-specific uptake and enhance
tumor accumulation, which is currently under development in
our laboratory.
After fluorescent imaging, PA signals from GBP-FANP
accumulation in tumors were measured. Compared to the
signals in tumor blood vessels, there was a significant PA
signal increase after GBP-FANP injection, which peaked at
24 h p.i. (Fig. 5c and d). Similarly, when GPC-3 was blocked by
addition of free GBP peptide, only weak PA signals were
noticed in the blocked group as well as in PC3 tumors, in
which the signals were mainly generated by the passive
enhanced permeable retention (EPR) effect. MRI imaging was
also performed in order to further confirm the accumulation
of GBP-FANP in HepG2 and PC3 tumors. As Fig. 5e and f
show, the T2 signal in PC3 tumors was not found to be affected
much due to the lack of GPC-3 target (T2 value: 116.37 ± 25.32)
compared with the signal before GBP-FANP was injected (T2
value: 125.86 ± 18.91). On the contrary, T2 signals significantly
decreased after GBP-FANP administration in HepG2 tumors
from 138.29 ± 16.11 to 69.86 ± 9.72. Overall, the above fluo-
rescent/PA/MRI imaging results confirmed that the tumor
accumulation of FANP is mediated through GBP binding with
GPC-3. As such, it is considered that GPC-3 is promising for
targeted therapy.
Photothermal therapy of GPC-3 positive tumors in mouse
models
HCC is typically aggressive and intrinsically resistant to stan-
dard chemotherapeutic agents, underscoring the need for
developing more effective therapies for HCC patients. As a
Fig. 6 Photothermal effect of GBP-FANP. (a) Thermal images of HepG2 and PC3 tumor-bearing mice intravenously treated with GBP-FANP at
10 mg kg−1 and exposed to 630 nm laser irradiation (1 W cm−2, 10 min) at 24 h post GBP-FANP was injected. White circle indicates the tumor
location. (b) Heating curves of HepG2 and PC3 tumors received GBP-FANP treatment with laser irradiation. (c) HepG2 and PC3 tumor growth curves
received different treatments after PTT. Error bars represent the standard deviations of 5 mice per group, P < 0.05. (d) Body weight curves of HepG2
and PC3 tumor-bearing mice in different groups. The error bars represent the standard deviations of 5 mice per group. Scale bar equals to 20 µm.
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noninvasive, harmless and highly efficient technique for
cancer therapy, PTT has aroused much attention recently.
An image-guided PTT was carried out to investigate
GBP-FANP ablation of HepG2 tumors in a mouse model.
According to the dynamic NIR fluorescence and PA imaging,
PTT was performed at 24 h p.i. when GBP-FANP accumulation
peaked in tumors to obtain the maximum efficacy. HepG2
tumors received PBS and GBP-FANP administration intra-
venously. To verify the specificity of GBP-FANP in HepG2
tumors, a 10-fold excess amount of free GBP peptide was
injected 30 min prior to GBP-FANP administration to saturate
GPB-3 binding sites. GPC-3 negative tumors, PC3, were used as
a control. After laser irradiation (630 nm, 1 W cm−2, 10 min),
tumor temperature changes were recorded using an infrared
thermal camera. As shown in Fig. 6a and b, the tumor temp-
erature increased from 30 °C to 54.63 °C ± 1.41 °C in HepG2
tumors with GBP-FANP treatment, which is sufficient to
induce irreversible tumor damage as a PTT agent. On the con-
trary, the temperature in PC3 tumors was also slightly
increased due to the non-specific accumulation of GBP-FANP.
No obvious body temperature changes were detected in PBS
administrated groups even with laser irradiation, indicating
Fig. 7 (a) Typical photographs of HepG2 and PC3 tumor-bearing mice after GBP-FANP treatment. H&E stained tumor sections of HepG2 and PC3
tumor-bearing mice in different groups post treatment. (b) Histological images of major organs using H&E staining. No noticeable abnormality was
found in the heart, liver, spleen, lung, or kidney.
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that GBP-FANP not only specifically targeted and accumulated
in GPC-3 positive tumors, but GBP-FANP also presented
efficient photo-thermal conversion effect for PTT tumor
ablation.
After treatment, tumor size and mice body weight were
monitored every other day. As presented in Fig. 6c, HepG2
tumors grew quickly without treatment. No tumor growth was
affected in GBP-FANP treated groups without laser irradiation,
indicating that laser irradiation is required for GPB-FANP
mediated tumor treatment. As expected, when HepG2 tumors
were administered with GBP-FANP and laser irradiation,
growth was significantly inhibited, and tumor volume
decreased. After a week, HepG2 tumors disappeared without
recurrence in our study. To clarify the PTT effect of GBP-FANP,
we also studied the tumor ablation effect of laser and found
that HepG2 tumors were only slightly inhibited compared to
the GBP-FANP treated group. Because of the poor targetability
of GBP-FANP, we did not observe much tumor ablation in the
PC3 tumor model regardless of laser irradiation, suggesting
that GBP-FANP mediated PTT is GPB-3 specific. Throughout
our study, no obvious body weight changes were found
(Fig. 6d).
Ex vivo study of the GBP-FANP treatment response by
histological staining
To further confirm the effective ablation of tumors with
GBP-FANP, tumor tissues and normal organs of mice received
treatments as indicated above and were collected at 3 days post
treatment with laser irradiation. These tissues were subjected
to a histological examination. In GBP-FANP treated tumors,
the tumor tissue structure was significantly damaged by PTT
and few tumor cells remained (Fig. 7a), which is attributable
to the effective tumor inhibition. In comparison, the tumor
tissue in PBS and laser treated groups was normal. No appar-
ent abnormality was found in the PC3 tumor either, suggesting
that such targeted PTT is specific and efficient. In normal
organs including liver, spleen, kidney, heart, and lung
(Fig. 7b), no obvious histologic changes were noticed for all
treated groups. These findings verified that GBP-FANP was
notably effective in ablating tumor growth by PTT and was not
toxic to normal organs.
Conclusion
In conclusion, we successfully constructed a GPC-3 targeted
hybrid Fe3O4 Core/Au Shell Nanocomplex (FANP) for fluo-
rescent/MRI/PA imaging guided tumor PTT. GBP peptide was
originally obtained by the phage display screening technique
and was modified onto the surface of FANP. Due to the poly-
valency and multimerization effects, the avidity between GBP
and GPC-3 was improved, which further leads to effective
tumor targeting and therapy response when combined with
FANP. As a result, GBP-FANP demonstrated excellent HCC
tumor ablation by PTT with minimal toxicity and side effects.
Taking in vitro and in vivo results together, our present results
offer a way of utilizing nanotechnology for furthering the
applications of phage display peptides in cancer theranostics.
Materials and methods
Cell culture
Human liver carcinoma cells (HepG2) and human prostate
cancer cells (PC3) were purchased from American Type Culture
Collection (ATCC) and incubated in DMEM medium and
1640 medium containing 10% FBS and 1% antibiotics (peni-
cillinstreptomycin, 10 000 U mL−1) at 37 °C in a humidified
atmosphere containing 5% CO2, respectively.
Peptide synthesis and labeling
Side chain protected GPC3 binding peptide (GBP) with the
sequence of THVSPNQGGLPS was synthesized using solid
phase peptide synthesizer (CS Bio Co. Inc.) with acid sensitive
resin and purified by high performance liquid chromato-
graphy (HPLC) on a C18 column. For purification, the flow rate
was set as 3 mL min−1, with a linear gradient of 10% to 55%
acetonitrile/water (0.1% trifluoroacetic acid) over 30 min (C18
column, 5 μm, 250 × 20 mm). The collected fractions were ana-
lyzed by analytical HPLC, using 5% to 65% acetonitrile con-
taining 0.1% TFA versus distilled water containing 0.1% TFA
over 30 minutes at a flow rate of 1 mL min−1 (C18 column,
5 μm, 120 A, 250 × 4.6 mm). Cy5.5 succinimide ester (Cy5.5-
NHS, 1 mg) was coupled to the N-terminus of GBP (3 mg) in
anhydrous dimethylformamide (DMF, 400 µL) containing 10%
of diisopropylethylamine (DIPEA) at room temperature in the
dark, and further purified by semipreparative HPLC under the
same conditions. Side chain protection groups were finally
removed in TFA cocktail and precipitated in cold ether. The
purified product was lyophilized as blue color powder and
characterized by analytical HPLC. The exact mass weight of the
Cy5.5 conjugated GBP (Cy5.5-GBP) was determined using elec-
trospray mass spectrometry with a monoisotopic molecular
weight of 1757.9 Da.
Synthesis of Fe3O4 iron oxide core/Au shell hybrid nanoparticle
(FANP)
The iron oxide core was prepared by coprecipitation approach.
Briefly, 2.6 g of FeCl3 and 1.0 g of FeCl2 were dissolved in HCl
solution (0.4 M), and the solution was added dropwise into
NaOH solution (125.0 mL, 1.5 M) with vigorous stirring. The
generated black precipitate was collected using a magnet, and
the supernatant was removed from the precipitate by decanta-
tion. After being washed three times using water, HCl solution
(250.0 mL, 0.01 M) was added to neutralize the anionic
charges of the precipitate. The resulting Fe3O4 NPs were
obtained after washing with water and dried.
FANPs were synthesized through the deposition of Au on
Fe3O4 NPs as reported.
38,51,52 First, Fe3O4 NPs (19.5 µL 64 mg
mL−1) were dispersed in BPS under continuous stirring and
dopamine (1.5 mg) was added to the solution at room temp-
erature for 3 h. Subsequently, the resultant product was separ-
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ated, washed and collected with a magnet. Then, sodium
citrate (2.0 mL, 10 mmol L−1) was added and sonicated for
15 min to exchange adsorbed OH− with citrate anions. At last,
the solution was heated to 130 °C, and 4.4 µL of HAuCl4 solu-
tion (239 mg mL−1) was added dropwise under stirring over
10 min, after which NH3·H2O (20%, 10 mL) was added. After
1 h reaction, the FANP was magnetically separated, washed
and dispersed in deionized water at 4 °C.
The preparation of GPC3 targeting FANP complex
Lipoic acid PEG amine (50 mg) was added to 4 mL FANP nano-
particles (containing 1 mg mL−1 of Au) in water. The mixture
was shaken gently overnight in the dark at room temperature.
The particles conjugated with PEG linker were then collected
by Centricon (cut off = 100 kDa) washed and dispersed in
water. Next, 1.0 mg Cy5.5 conjugated GPC3 binding peptide
(GBP) was dissolved in 1 mL DMSO. 1-Ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide
(NHS) were added to the solution to activate –COOH in Cy5.5-
GBP. After 30 min, the mixture was added to the FANP with
lipoic acid PEG amine linker solution. The reaction was
shaken gently overnight in the dark at room temperature and
the final product was purified by Centricon (cut off = 100 kDa).
At last, the purified product, GBP-FANP, was dispersed in
water for further applications.
Characterization of FANP and FANP-GBP
Transmission electron microscopy images were taken using a
Bruker transmission electron microscope operating at an accel-
eration voltage of 200 kV. The hydrodynamic size (Z-Average) of
FANP and FANP-GBP were determined by DLS (NanoZS,
Malvern Instrument, Worcestershire, UK) using disposable
square polystyrene cuvettes (Malvern Instrument, UK) at 25 °C.
The absorbance of FANP and FANP-GBP were measured
by UV-vis-NIR spectrometer (Thermo Fisher Scientific,
Massachusetts, USA). The fluorescence values of Cy5.5-GPB
and FANP-GBP were measured by fluorescent spectrometer
(PerkinElmer, USA).
The concentration of Fe3O4 was determined by inductively
coupled plasma atomic emission spectroscopy (ICP-AES).
FANPs at different concentrations were dispersed in distilled
water (5, 10, 25, 50, 100 µg mL−1). T2-Weighted MRI was
measured with a 9.4 T MRI system (Bruker, Massachusetts, US)
using a conventional spin-echo sequence. PA signals of FANP
were imaged and analyzed by Endra Nexus128 (Ann Arbor, MI,
USA).
ELISA
To calculate the apparent Kd value between the human recom-
binant GPC3 protein and GBP and GBP-FANP, the human
recombinant GPC3 protein (100 ng per well) was immobilized
on a 96-well plate at 4 °C overnight. Next day, the human
recombinant GPC3 protein was incubated with eight gradient
diluted concentrations of biotin-GBP or biotin-GBP-FANP at
37 °C for 1 h (n = 3). To detect the bound GBP and GBO-FANP,
horseradish peroxidase (HRP)-conjugated avidin (AB11037,
Life Science Product & Services, Inc.) was used as the second
antibody (1 : 3000 dilution). After 1 h incubation at 37 °C,
100 μL 3,3′,5,5′-tetramethylbenzidine (TMB) (Sangon Biotech,
Inc.) was added to each well, and the plate was kept in the
dark for 15 min at 37 °C. 50 μL of 1 N H2SO4 was then added
to each well to stop the reaction. At the end of the test, the
absorbance at 450 nm of the 96-well plate was measured in
microtiter plate reader (Thermo Scientific, USA). Accordingly,
the apparent Kd value was calculated with GraphPad Prims
software.
In vitro photothermal effect of FANP
To evaluate the photothermal behavior of FANPs, a 100 µL
solution of FANP was irradiated using a NIR laser (630 nm, 1.0
W cm−2) for 10 min. The laser spot covered the entire surface
of samples. Thermal images of different solutions were
acquired real-time by FLIR Ax5 camera (FLIR Systems Inc.,
Wilsonville, USA) and quantified by BM_IR software (FLIR
Systems Inc., Wilsonville, USA).
Cell viability assay
The HepG2 and PC3 cells were seeded in 96-well plates with a
density of 104 cells per well. 12 h prior to assay, the cells were
exposed to FANPs at various concentrations (0, 25, 50, 75, 100,
150 µg mL−1 of Au concentration) with or without NIR illumi-
nation (1 W cm−2, 630 nm, 10 min). After incubation at 37 °C
for another 4 h, the cells were incubated with 0.5 mg mL−1
MTT in DMEM or RPMI 1640 for 4 h in dark and then mixed
with dimethyl sulfoxide after the supernatant was removed.
The OD value at 570 nm was read using a microplate reader.
Cell viability was determined by the percentage of OD value of
the study group over the control group.
In vivo imaging of HepG2 and PC3 tumor with FANP-GBP
All animal procedures were performed in accordance with the
National Institutes of Health Guidelines for the Care and Use
of Laboratory Animals and were approved by the Animal Ethics
Committee of Jilin University. Subcutaneous sites of athymic
nude mice (seven weeks old, female, 16–18 g) were injected
with a suspension of 4 × 106 HepG2 and PC3 cells in PBS
(100 µL). Tumors were inoculated on shoulders to avoid the
background affection from stomach, while the tumors were
implanted on the lower back due to the easy measurement.
When the tumors reached an average size of 80–100 mm3,
mice were randomly allocated into three groups: HepG2 tumor
bearing mice received FANP-GBP (10 mg kg−1 equivalent dose
of Au, HepG2 tumor bearing mice received free GBP peptide
and FANP-GBP (10 mg kg−1 equivalent dose of Au), and PC3
tumor bearing mice received FANP-GBP (10 mg kg−1 equi-
valent dose of Au. To verify the specific binding of GPB to
HepG2 tumors, free GBP peptide (2 mg) was injected into
HepG2 tumor bearing mice to block GPC-3 30 min ahead of
FANP-GBP intravenous administration. Fluorescent images
were acquired at 1, 2, 4, 6, 12, 24, 48, and 72 h after injection
using IVIS Lumina II (Caliper Life Sciences, USA; Excitation
Filter: 640 nm, Emission Filter: 700 nm) and PA imaging in
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the tumor sites on Endra Nexus128 (Ann Arbor, MI, USA). T2-
Weighted and T2-map MR images were taken before and 24 h
after FANP-GBP administration in HepG2 and PC3 tumors. R2
relaxivities were analyzed to assess nanoparticle accumulation
in the tumors.
In vivo photothermal therapy
Athymic nude mice (six weeks old, female, 20–24 g) were pur-
chased from Shanghai Slac Laboratory Animal CO. Ltd. HepG2
and PC3 cells (4 × 106 cells in 100 µL of PBS) were injected in
the right leg of athymic nude mice (seven weeks old, 16–18 g).
When the tumors reached an average size of 100–120 mm3, the
tumor-bearing mice (n = 5 per group) were randomly divided
into six groups: (1) non-treated group with HepG2 tumor; (2)
laser (630 nm, 1.0 W cm−2, 10 min) irradiated group with
HepG2 tumor; (3) FANP-GBP without laser irradiation group
with HepG2 tumor; (4) FANP-GBP with laser (630 nm, 1.0 W
cm−2, 10 min) irradiation group with HepG2 tumor; (5)
FANP-GBP without laser irradiation group with PC3 tumor;
and (6) FANP-GBP with laser (630 nm, 1.0 W cm−2, 10 min)
irradiation group with PC3 tumor. All mice received 10 mg
kg−1 equivalent dose of Au in FANP intravenously. The tem-
perature changes under laser illumination of the tumor area
were recorded with thermal images using a FLIR Ax5 camera
and quantified by BM_IR software. The weight of mice and
tumor growth were monitored every two days. Tumor size was
measured by a caliper and tumor volume was determined
using the following formula V = W2 × L/2, where W and L were
the shortest and longest diameters of tumors, respectively. On
day 15 after treatment, all mice were sacrificed, and the
tumors were collected and weighed. The main organs (heart,
liver, spleen, lung, and kidney) of the mice were also harvested
and used for histology analysis.
Histological studies
Normal organs and tumors were fixed in a 4% formaldehyde
solution at room temperature for 48 h for haematoxylin and
eosin (H&E) analysis. The 5 µm tissue sections were stained
with H&E staining, using a standard protocol. All tissue sec-
tions were examined under microscope.
Statistical analysis
Statistical analysis was performed using one-way ANOVA fol-
lowed by Bonferroni multiple comparison test. P < 0.05 was
considered statistically significant.
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